About 300 reports

  • PFIZER INC. - MAJOR BIOSIMILARS APPROVED FOR MARKETING
  • AUSTRALIA: BIOSIMILAR MEDICINES APPROVED AND LISTED ON THE PHARMACEUTICAL BENEFITS SCHEME
  • Biotechnology
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited
  • ZARXIO: PARAMETERS TO TEST SIMILARITY
  • BIOSIMILARS: EVOLUTION IN THE GLOBAL REGULATORY ENVIRONMENT
  • Biosimilar
  • Biotechnology
  • World
  • Market Size
  • Remicade group
  • Strength 1 Low; 5 High
  • First biosimilar approved in Americas
  • Biotechnology
  • Europe
  • Amgen Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • LIST OF APPROVED BIOSIMILARS FOR GRANULOCYTE COLONY-STIMULATING FACTOR PRODUCTS FROM 2013 TO 2016
  • BIOSIMILAR RECOMBINANT HUMAN GROWTH HORMONE MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • Biosimilar
  • Biotechnology
  • World
  • Market Size
  • Sandoz Inc.
  • Biosimilars approved by PMDA in Japan
  • Assumptions
  • Biotechnology
  • Biocon Limited
  • Hospira, Inc.
  • Sandoz Inc.
  • Teva Pharmaceuticals Ltd.
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM - DRUG PROFILE
  • Biosimilar
  • Biotechnology
  • Chemotherapy
  • Therapy
  • Coherus BioSciences, Inc.
  • filgrastim - Drug Profile
  • Biocon Limited - Early Stage Pipeline Products
  • Biotechnology
  • India
  • World
  • Product Initiative
  • Biocon Limited
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM - DRUG PROFILE
  • Biotech
  • Biotechnology
  • Chemotherapy
  • Pharmaceutical
  • Therapy
  • US Approved Biosimilars
  • 2.3 BIOSIMILARS OVERVIEW
  • Biotechnology
  • World
  • Boehringer Ingelheim GmbH
  • Lonza Group Ltd
  • Samsung Electronics Co., Ltd.
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM - DRUG PROFILE
  • Biosimilar
  • Biotechnology
  • United States
  • Product Initiative
  • Coherus BioSciences, Inc.
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM BIOSIMILAR - DRUG PROFILE
  • Biosimilar
  • Biotechnology
  • United States
  • Product Initiative
  • Coherus BioSciences, Inc.
  • US Approved Biosimilars
  • 2.3 Overview of Biosimilars
  • Biotechnology
  • Amgen Inc.
  • Celltrion, Inc.
  • Pfizer Inc.
  • Sandoz Inc.

Filgrastim – Introduction ##.

  • Biological Therapy
  • Biotechnology
  • Filgrastim
  • World
  • Demand
  • 6.3 RECOMBINANT GROWTH FACTOR
  • Financial Overview (in EUR million)

It has received approval for tbo-filgrastim (XM## filgrastim).

  • Biotechnology
  • Biocon Limited
  • Hospira, Inc.
  • Mylan Inc.
  • Sandoz Inc.
  • FILGRASTIM - DRUG PROFILE
  • FEBRILE NEUTROPENIA - PIPELINE BY BIOGENOMICS LIMITED, H1 2016
  • Biotechnology
  • Therapy
  • United States
  • World
  • Product Initiative
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY BIOGENOMICS LTD
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY MYCENAX BIOTECH INC
  • Biotechnology
  • Chemotherapy
  • Gastrointestinal Drug
  • Neurological Disorder
  • Pharmaceutical
  • Clinical Trial profile. 7 Trial Title
  • Therapy Area Indication(s)
  • Biotechnology
  • Clinical Trial
  • Leukemia
  • Lymphoma
  • Monoclonal Antibody
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Dormant Projects
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Dormant Products
  • Biotechnology
  • Blood Supply
  • Prostate Cancer
  • Therapy
  • OncBioMune Pharmaceuticals, Inc.
  • Geographical segmentation

In 2012, Novartis initiated Phase III studies for biosimilars such as Epoetin Alfa, Filgrastim, and Pegfilgrastim.

  • Biotechnology
  • AbbVie Inc.
  • Amgen Inc.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Target
  • Clinical Trial profile. 5 Trial Title
  • Biotechnology
  • Chemotherapy
  • Therapy
  • World
  • Product Initiative
  • Amgen, Inc.: key facts

Amgen markets Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the US and Europe.

  • Biotechnology
  • Amgen Inc.
  • Covance Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Untitled

Consequent to the approval of Novartis' filgrastim biosimilar in the US-the first biosimilar to receive FDA approval-it is expected that the focus on biosimilars will increase in the country.

  • Biotechnology
  • Cancer
  • Charles River Laboratories International, Inc.
  • Horizon Discovery
  • WuXi AppTec Co.
  • Official Title
  • Clinical Trial profile. 44 Trial Title
  • Anti-Infective
  • Biotechnology
  • Blood Disease
  • Chemotherapy
  • Clinical Trial
  • NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • BIOSIMILARS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)

One of the important milestones realized on this front was the FDA approval for Sandoz' s (Germany) filgrastim biosimilar-Zarxio (filgrastim-sndz)-for all five indications of the originator product-Neupogen-in 2015.

  • Biotechnology
  • Asia
  • Europe
  • World
  • Market Size

Pfenex Inc. - Product Pipeline Review - 2016 Reference Code: GMDHC##CDB Publication Date: JUN 2016 © Global Markets Direct.

  • Biosimilar
  • Biotechnology
  • World
  • Product Initiative
  • Pfenex Inc.
  • PEGYLATED PROTEINS MARKET SIZE FOR COLONY-STIMULATING FACTORS, BY REGION, 2014-2021 (USD MILLION)
  • 8.1 INTRODUCTION

PEG-FILGRASTIM (PEG-GCSF) MARKETED AS NEUPOGEN BY AMGEN, INC.

  • Biotechnology
  • Blood Disease
  • Colony-Stimulating Factor
  • Erythropoietin
  • Pharmaceutical
  • filgrastim alone or in combination has the highest number of neutropenia ongoing clinical trials.
  • Clinical Trial profile. 13 Trial Title
  • Biotechnology
  • Blood Disease
  • World
  • Product Initiative
  • Amgen Inc.
  • Amgen, Inc.: key facts

Amgen markets Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the US and Europe.

  • Biotechnology
  • World
  • Forecast
  • Market Size
  • Amgen Inc.
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM - DRUG PROFILE
  • Biotech
  • Biotechnology
  • Chemotherapy
  • Filgrastim
  • Pharmaceutical

Filgrastim in Treating Patients with Burkitt' s Lymphoma or Burkitt' s Leukemia GDCT## NCT##, U##CA##; CALGB-##; CDR## Oncology Burkitt Lymphoma, Leukemias, Lymphoma Completed Phase II Interventional allopurinol; cyclophosphamide; cytarabine; dexamethasone; doxoru

  • Biotechnology
  • Cancer
  • Cell Therapy
  • Lymphoma
  • Monoclonal Antibody